Q1. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:
a. Afatinib
b. Alectinib
c. Amivantamab
d. Atezolizumab monotherapy
e. Atezolizumab with chemotherapy
f. Brigatinib
g. Ceritinib
h. Crizotinib
i. Dacomitinib
j. Dabrafenib with Trametinib
k. Durvalumab
l. Erlotinib
m. Gefitinib
n. Lorlatinib
o. Mobocertinib
p. Nintedanib with Docetaxel
q. Nivolumab
r. Osimertinib
s. Pembrolizumab monotherapy
t. Pembrolizumab with chemotherapy
u. Pemetrexed with Carboplatin/Cisplatin
v. Pralsetinib
w. Selpercatinib
x. Sotorasib
y. Tepotinib
z. Vinorelbine with Carboplatin/Cisplatin
aa. Any other active systemic anti-cancer therapy (SACT)
bb. Palliative care only
Q2. In the past 3 months, how many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY with the following drugs:
a. Atezolizumab monotherapy
b. Atezolizumab with chemotherapy
c. Durvalumab
d. Nivolumab
e. Osimertinib
f. Pembrolizumab (Keytruda) Mono
g. Pembrolizumab (Keytruda) with Chemotherapy
h. Tepotinib
i. Other active systemic anti-cancer therapy (SACT)
j. Palliative care only
Q3. Do you participate in any clinical trials for non-small cell lung cancer (NSCLC)? If so, could you please provide the name of each trial and the number of patients taking part.